← Leaderboards
Jerry Mendell
Ohio State University
$11,877,761
Attributed
$12,350,772
Total exposure
24
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$25,282,784 · 24
CDC$1,662,500 · 2
By mechanism
U54$18,881,038 · 7
U01$2,060,015 · 1
M01$1,638,181 · 13
R01$1,354,652 · 1
R18$1,350,000 · 1
T32$946,023 · 1
Top collaborators
- Denis C Guttridge5 shared
Most similar at Ohio State University
Same institution · by research overlap
- John C Kissel$1,216,123
- Liva Harinantenaina Rakotondraibe$586,807
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsHuman SubjectDystrophinGene TherapyGene TransferMuscleMuscular Dystrophy, DuchenneHuman Therapy EvaluationMuscular DystrophiesBlood VesselsSafetyTransgenesGenesGene ExpressionBlood CirculationDrug Screening /EvaluationEnsureSuccessResearch PersonnelMuscle StrengthSiteMicro-DystrophinMuscular Dystrophy
Grant awards (72)
Training in neuromuscular diseases$152,565
T32 · FY2016 · NS
Training in neuromuscular diseases$204,187
T32 · FY2015 · NS
Dual-vector mediated mini-dystrophin restoration of function in mdx model of DMD$183,125
R21 · FY2015 · NS · contact PI
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy$1,278,703
U54 · FY2014 · HD · contact PI
The Implications of Dystrophin-Specific T cells for DMD gene Correction$268,331
U54 · FY2014 · HD · contact PI
Dual-vector mediated mini-dystrophin restoration of function in mdx model of DMD$219,750
R21 · FY2014 · NS · contact PI
Training in neuromuscular diseases$201,011
T32 · FY2014 · NS
Administrative Core$133,613
U54 · FY2014 · HD · contact PI
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy$1,262,994
U54 · FY2013 · HD · contact PI
Vascular Delivery of alpha-Sarcoglycan for LGMD2D$496,299
U01 · FY2013 · AR · contact PI
The Implications of Dystrophin-Specific T cells for DMD gene Correction$295,111
U54 · FY2013 · HD · contact PI
Training in neuromuscular diseases$195,737
T32 · FY2013 · NS
Administrative Core$115,939
U54 · FY2013 · HD · contact PI
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy$1,353,968
U54 · FY2012 · HD · contact PI
Vascular Delivery of alpha-Sarcoglycan for LGMD2D$522,420
U01 · FY2012 · AR · contact PI
The Implications of Dystrophin-Specific T cells for DMD gene Correction$367,046
U54 · FY2012 · HD · contact PI
Training in neuromuscular diseases$192,523
T32 · FY2012 · NS
Administrative Core$128,751
U54 · FY2012 · HD · contact PI
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy$1,359,974
U54 · FY2011 · HD · contact PI
Vascular Delivery of alpha-Sarcoglycan for LGMD2D$1,041,296
U01 · FY2011 · AR · contact PI
The Implications of Dystrophin-Specific T cells for DMD gene Correction$405,634
U54 · FY2011 · HD · contact PI
Administrative Core$125,758
U54 · FY2011 · HD · contact PI
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)$1,555,326
U54 · FY2010 · NS · contact PI
Overcoming Immune Barriers to Gene Correction for Duchenne Muscular Dystrophy$1,400,132
U54 · FY2010 · HD · contact PI
The Implications of Dystrophin-Specific T cells for DMD gene Correction$316,298
U54 · FY2010 · HD · contact PI
Dystrophin Restoration$259,218
U54 · FY2010 · NS · contact PI
Administrative Core$91,672
U54 · FY2010 · HD · contact PI
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)$2,112,675
U54 · FY2009 · NS · contact PI
Implementing Newborn Screening for Duchenne Muscular Dystrophy in the Community$450,000
R18 · FY2009 · DD · contact PI
Dystrophin Restoration$352,110
U54 · FY2009 · NS · contact PI
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)$2,051,556
U54 · FY2008 · NS · contact PI
Implementing Newborn Screening for Duchenne Muscular Dystrophy in the Community$450,000
R18 · FY2008 · DD · contact PI
Dystrophin Restoration$341,924
U54 · FY2008 · NS · contact PI
Developing Clinical Outcomes for Gene Transfer$170,088
U54 · FY2008 · AR · contact PI
CLINICAL TRIAL: SIX-MONTH (26 WEEKS) CLINICAL TRIAL OF GENTAMICIN IN DUCHENNE MD$1,733
M01 · FY2008 · RR · contact PI
Diverse Strategies to Correct the Dystrophin Gene Using Vascular Delivery (U54)$2,219,184
U54 · FY2007 · NS · contact PI
Implementing Newborn Screening for Duchenne Muscular Dystrophy in the Community$450,000
R18 · FY2007 · DD · contact PI
Administrative Core$317,026
U54 · FY2007 · NS · contact PI
Dystrophin Restoration$317,025
U54 · FY2007 · NS · contact PI
Developing Clinical Outcomes for Gene Transfer$280,982
U54 · FY2007 · AR · contact PI
SIX-MONTH (26 WEEKS) CLINICAL TRIAL OF GENTAMICIN IN DUCHENNE MD$105,399
M01 · FY2007 · RR · contact PI
Newborn Screening for Duchenne Muscular Dystrophy$62,500
U50 · FY2007 · DD · contact PI
STUDY OF MYO-029$26,503
M01 · FY2007 · RR · contact PI
STUDY OF SR 57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$1,849
M01 · FY2007 · RR · contact PI
Newborn Screening for Duchenne Muscular Dystrophy$250,000
U50 · FY2006 · DD · contact PI
SIX-MONTH (26 WEEKS) CLINICAL TRIAL OF GENTAMICIN IN DUCHENNE MD$47,750
M01 · FY2006 · RR · contact PI
Newborn Screening for Duchenne Muscular Dystrophy$0
U50 · FY2005 · DD
Gentamicin Trial in Duchenne and Limb Girdle Dystrophies$428,558
R01 · FY2004 · NS
Newborn Screening for Duchenne Muscular Dystrophy$0
U50 · FY2004 · DD
Gentamicin Trial in Duchenne and Limb Girdle Dystrophies$462,704
R01 · FY2003 · NS
Developing Clinical Outcomes for Gene Transfer$0
U54 · FY2003 · AR
Gentamicin Trial in Duchenne and Limb Girdle Dystrophies$463,390
R01 · FY2002 · NS
EFFICACY OF SR57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$193,916
M01 · FY2001 · RR
LGMD STUDY GROUP$193,916
M01 · FY2001 · RR
GREAT LAKES ALS STUDY GROUP$193,916
M01 · FY2001 · RR
EFFICACY, SAFETY, TOLERABILITY OF SR57746A IN ALS PATIENTS$193,916
M01 · FY2001 · RR
CLINICAL TRIAL OF OXANDRIN IN TREATMENT OF DUCHENNES MUSCULAR DYSTROPHY$193,916
M01 · FY2001 · RR
INTRAVENOUS IMMUNOGLOBULIN IN CIPD$193,916
M01 · FY2001 · RR
INTRAVENOUS IMMUNOGLOBULIN IN CIPD$48,578
M01 · FY2000 · RR
GREAT LAKES ALS STUDY GROUP$48,578
M01 · FY2000 · RR
EFFICACY, SAFETY, TOLERABILITY OF SR57746A IN ALS PATIENTS$48,578
M01 · FY2000 · RR
CLINICAL TRIAL OF OXANDRIN IN TREATMENT OF DUCHENNES MUSCULAR DYSTROPHY$48,578
M01 · FY2000 · RR
EFFICACY OF SR57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$48,578
M01 · FY2000 · RR
LGMD STUDY GROUP$48,561
M01 · FY2000 · RR
LGMD STUDY GROUP$0
M01 · FY2000 · RR
CLINICAL TRIAL OF OXANDRIN IN TREATMENT OF DUCHENNES MUSCULAR DYSTROPHY$0
M01 · FY2000 · RR
EFFICACY OF SR57746A IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$0
M01 · FY2000 · RR
EFFICACY, SAFETY, TOLERABILITY OF SR57746A IN ALS PATIENTS$0
M01 · FY2000 · RR
TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS USING A KETOGENIC DIET$0
M01 · FY2000 · RR
TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS USING A KETOGENIC DIET$0
M01 · FY2000 · RR
SAFETY, EFFICACY AND TOLERABILITY OF BETA INTERFERON1A IN INCLUSION BODY MYOSITIS$0
M01 · FY2000 · RR
SAFETY, EFFICACY AND TOLERABILITY OF BETA INTERFERON1A IN INCLUSION BODY MYOSITIS$0
M01 · FY2000 · RR